HomeCompareNMTR vs YUM

NMTR vs YUM: Dividend Comparison 2026

NMTR yields 2770.08% · YUM yields 1.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NMTR wins by $212938372920.80M in total portfolio value
10 years
NMTR
NMTR
● Live price
2770.08%
Share price
$0.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$212938372920.91M
Annual income
$198,819,380,806,317,020.00
Full NMTR calculator →
YUM
YUM
● Live price
1.86%
Share price
$154.59
Annual div
$2.88
5Y div CAGR
51.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$107.9K
Annual income
$40,443.52
Full YUM calculator →

Portfolio growth — NMTR vs YUM

📍 NMTR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNMTRYUM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NMTR + YUM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NMTR pays
YUM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NMTR
Annual income on $10K today (after 15% tax)
$235,457.06/yr
After 10yr DRIP, annual income (after tax)
$168,996,473,685,369,470.00/yr
YUM
Annual income on $10K today (after 15% tax)
$158.35/yr
After 10yr DRIP, annual income (after tax)
$34,376.99/yr
At 15% tax rate, NMTR beats the other by $168,996,473,685,335,100.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NMTR + YUM for your $10,000?

NMTR: 50%YUM: 50%
100% YUM50/50100% NMTR
Portfolio after 10yr
$106469186460.51M
Annual income
$99,409,690,403,178,740.00/yr
Blended yield
93.37%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on YUM right now

NMTR
No analyst data
Altman Z
-49.9
Piotroski
2/9
YUM
Analyst Ratings
18
Buy
30
Hold
3
Sell
Consensus: Hold
Price Target
$173.15
+12.0% upside vs current
Range: $158.00 — $190.00
Altman Z
2.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NMTR buys
0
YUM buys
0
No recent congressional trades found for NMTR or YUM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNMTRYUM
Forward yield2770.08%1.86%
Annual dividend / share$2.00$2.88
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.4%
Portfolio after 10y$212938372920.91M$107.9K
Annual income after 10y$198,819,380,806,317,020.00$40,443.52
Total dividends collected$211957883813.74M$81.2K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: NMTR vs YUM ($10,000, DRIP)

YearNMTR PortfolioNMTR Income/yrYUM PortfolioYUM Income/yrGap
1← crossover$287,708$277,008.31$10,982$282.06+$276.7KNMTR
2$7,756,221$7,448,373.17$12,189$438.29+$7.74MNMTR
3$195,960,759$187,661,602.67$13,731$688.32+$195.95MNMTR
4$4,640,768,087$4,431,090,074.46$15,789$1,097.12+$4640.75MNMTR
5$103,038,191,206$98,072,569,353.09$18,679$1,785.08+$103038.17MNMTR
6$2,145,287,049,877$2,035,036,185,286.86$22,975$2,988.18+$2145287.03MNMTR
7$41,893,666,105,695$39,598,208,962,326.13$29,784$5,200.49+$41893666.08MNMTR
8$767,520,675,750,287$722,694,453,017,193.00$41,408$9,539.16+$767520675.71MNMTR
9$13,195,319,733,262,706$12,374,072,610,209,900.00$63,071$18,765.27+$13195319733.20MNMTR
10$212,938,372,920,908,130$198,819,380,806,317,020.00$107,930$40,443.52+$212938372920.80MNMTR

NMTR vs YUM: Complete Analysis 2026

NMTRStock

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.

Full NMTR Calculator →

YUMConsumer Discretionary

YUM! Brands, Inc., together with its subsidiaries, develops, operates, and franchises quick service restaurants worldwide. It operates through four segments: the KFC Division, the Taco Bell Division, the Pizza Hut Division, and the Habit Burger Grill Division. The company operates restaurants under the KFC, Pizza Hut, Taco Bell, and The Habit Burger Grill brands, which specialize in chicken, pizza, made-to-order chargrilled burgers, sandwiches, Mexican-style food categories, and other food products. As of December 31, 2021, it had 26,934 KFC units; 18,381 Pizza Hut units; 7,791 Taco Bell units; and 318 The Habit Burger Grill units in approximately 157 countries and territories. The company was formerly known as TRICON Global Restaurants, Inc. and changed its name to YUM! Brands, Inc. in May 2002. YUM! Brands, Inc. was incorporated in 1997 and is headquartered in Louisville, Kentucky.

Full YUM Calculator →
📬

Get this NMTR vs YUM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NMTR vs SCHDNMTR vs JEPINMTR vs ONMTR vs KONMTR vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.